

November 05, 2020

Impressive Performance Despite Q2 Headwinds

9M Topline Performance Hoisted by Volume Growth in Q3:2020

The 9M:2020 financial scorecard of Lafarge Africa Plc. (WAPCO) showed that revenue performance bettered the corresponding period last year. Unhindered by setbacks from the COVID-19 containment measures in Q2:2020, revenue grew by 10.32%YoY from NGN163.06bn in 9M:2019 to NGN179.88bn. The impressive outing was due to significant growth in sales volume (+29.70%) in the quarter. Although revenue from aggregates and concretes slipped by 29.86%, its effect was cushioned by an 11.45% YoY jump in cement revenue (c.98% of total revenue). As the company continues to push for a larger market share by strengthening its distribution network, we expect to see volumes growth in subsequent quarters. We are also optimistic about the prospect of the cement market in Nigeria. We anticipate that cement makers would continue to enjoy robust demand driven by the existing infrastructure gap and the recognition of concrete-based roads as a viable alternative to asphalt. For 2020FY, we estimate a total turnover of NGN230.42bn (compared to our previous forecast of NGN216.48bn) based on a revised capacity utilization of 57% (vs 54% previously). This represents a growth of 8.18% when compared to NGN213.00bn in 2019FY.

Lower Finance Costs Boosts Bottomline Performance

During the period, the company continued to intensify efforts on cost optimization under its Health, Cost and Cash Initiative. So far, the result has been a reduction in the cost to sales ratio from 69.11% in 9M:2019 to 68.80% in 9M:2020 and a slightly lower OPEX to sales ratio (8.78% vs. 9.50% in 9M:2019). Although the company was able to reduce costs of production and overheads, the cost implications of the FX devaluation, especially on energy costs is high. Like its peers, we expect FX stability to be a key risk factor to put pressure on costs. However, topline gains and overall cost moderation ensured a slightly higher operating margin of 22.85% in 9M:2020 (vs 21.80% in 9M:2019). Hence, supported by a 54.51% decline in finance cost (a fall out of lower debt obligation as a result of the restructuring in 2019), profit after tax grew by 37.05% to NGN28.20bn in 9M:2020 (vs NGN20.57bn in 9M:2019).

Balance Sheet Health Unfazed by Pandemic

In our H1:2020 update, our assessment of the company's balance sheet showed the company to be in good financial health following the divestment of the South African subsidiary. As at 9M:2020, our view remains unchanged. Having preserved liquidity through the pandemic, the company's liquidity position as observed through the current ratio (0.83x vs 0.89x in 2019FY) and cash ratio (0.49x vs 0.32x in 2019FY) proved resilient to the effect of the pandemic. This is also true when viewed in comparison to peers (Current ratio; BUACEMENT- 0.62x; Cash ratio: BUACEMENT- 0.44x) and _ alongside the industry norm of working capital deficits . Free cashflow also improved by 94.50%YoY to NGN50.60bn during the period given the company's modest CAPEX and improved earnings. In our opinion, these coupled with impressive return to shareholders (34.38% vs 33.37% in 2019FY) and decent gearing (0.15x) highlight the company's financial strength.

Recommendation

For 2020FY, we revise our EBITDA forecast from NGN65.97bn to NGN68.48bn and maintain a target EV/EBITDA of 4.51x. We thereby arrived at a 2020FY price target of NGN19.88. At the current price of NGN18.50, the implied upside of 7.46% (relative to our 2020TP of NGN19.88) informed our HOLD rating on the counter.

Company	WAPCO
Valuation	
EPS	7.62
BVPS	22.16
P/E	2.42x
P/BV	0.83x
Target EV/EBITDA	4.51x
Dec-2020 Exp. EBITDA	
[NGN]	68.48bn
Dec 2020 Target price	19.88
Current Price	18.50
Up/Downside Potential	7.46%
Ratings	HOLD
Key metrics	
ROE	34.38%
ROA	24.03%
Net margin	53.40%
Asset Turnover	0.45x
Leverage	0.15x
Yr Hi	1.85
Yr Lo	8.95
YTD return	20.92%
Beta	0.13
Adjusted Beta	0.42
52-Week average volume	5.41mn
Shares outstanding	16.11bn
Market cap [NGN]	297.99bn
Financial year end	Dec
Most Recent Period (MRP)	9M:2020





November 05, 2020

Chart 1: Sensitivity Analysis

Sensitivity Analysis of Dec-2020 Target Price to key model inputs					Min	18.35		
		EBITDA per share				Max	21.46	
		7.10	7.29	7.48	7.66	7.85	_	
Towart EV/EDITO	4.28x	18.35	18.64	18.92	19.21	19.49	_	
	4.40x	18.82	19.11	19.40	19.69	19.98		
Target EV/EBITDA	4.51x	19.28	19.58	19.88	20.18	20.48		
	4.62x	19.75	20.05	20.36	20.67	20.97		
	4.74x	20.21	13.53	13.16	21.15	21.46	_	

E' ' LU' LU' LU 'NON ''' \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \			
Financial Highlights (NGN million) 9M:2020 Fin	ianciai result		
Profit & Loss Account	9M:2020	9M:2019	y/y Growth
Revenue	179,877	163,057	10.32%
Cost of Sales	123,755	112,690	9.82%
Gross Profit	56,123	50,367	11.43%
Investment Income	721	1,179	-38.79%
Other Income	810	600	35.05%
Operating Expense	15,791	15,488	1.95%
Finance Cost	7,541	16,578	-54.51%
PBT	34,291	20,139	70.27%
PAT	34,292	20,140	-70.27%
Balance Sheet	9M:2020	2019FY	
Inventories	30,356	32,441	-6.43%
Trade and other Receivables	5,105	8,193	-37.69%
Cash and bank	64,852	27,104	139.27%
Property, Plant and Equipment	351,458	369,797	-4.96%
Other Assets	58,917	59,617	-1.17%
Total Assets	510,688	497,152	2.72%
Shareholders' fund	357,003	344,914	3.50%
Trade and Other Payables	80,789	69,718	15.88%
Tax Liabilities	2,724	1,929	41.20%
Total Liabilities	2,732	1,946	40.38%



November 05, 2020

Contact Information

Brokerage and Retail Services

topeoludimu@meristemng.com (+234 905 569 0627) olatunjifaniyi@meristemng.com (+234 803 4463118) contact@meristemng.com

Investment Banking/Corporate Finance

rasakisalawu@meristemng.com (+234 806 022 9889) seunlijofi@meristemng.com (+234 808 536 5766)

Wealth Management

funmilolaadekola-daramola@meristemng.com (+234 805 498 4522)

crmwealth@meristemng.com

Tel: +234 01 738 9948

Registrars

muboolasoko@meristemregistrars.com (+234 803 324 7996) martinaosague@meristemregistrars.com (+234 802 303 1783)

www.meristemregistrars.com

Tel: +23401-280 9250

Group Business Development

saheedbashir@mersitemng.com (+234 802 454 6575) ifeomaogalue@meristemng.com (+234 802 394 2967) emekaikpechukwu@meristemng.com (+234 803 791 5731) info@meristemng.com

Client Services

adefemitaiwo@meristemng.com (+234 803 694 3034) blessingogwuche@meristemng.com (+234 706 896 5173)

car@meristemng.com

Investment Research

ahmedjinad@meristemng.com (+234 809 187 8917)

research@meristemng.com

Corporate websites: www.meristemng.com www.meristemwealth.com www.meristemregistrars.com

Meristem Research can also be accessed on the following platforms:

Meristem Research portal: meristem.com.ng/rhub

Bloomberg: MERI <GO>

Capital IQ: www.capitaliq.com Reuters: www.thomsonreuters.com

ISI Emerging Markets: www.securities.com/ch.html?pc=NG FactSet: www.factset.com



November 05, 2020

Analyst's Certification and Disclaimer

This research report has been prepared by the research analyst(s), whose name(s) appear(s) on the cover of this report. Each research analyst hereby certifies, with respect to each security or issuer covers in this research that:

- (1) all of the views expressed in this report accurately reflect his or her personal views about any and all of the subject securities or issuers (the Issuer); and
- (2) no part of any of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. Research analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Meristem Securities Limited (the Firm). Like all of the Firm's employees, research analysts receive compensation that is impacted by overall Firm profitability, which includes revenues from other business units within the Firm.
- (3) each research analyst and/or persons connected with any research analyst may have interacted with sales and trading personnel, or similar, for the purpose of gathering, synthesizing and interpreting non-material non-public or material public market information.

As at the date of this report, any ratings, forecasts, estimates, opinions or views herein constitute a judgment, and are not connected to research analysts' compensations. In the case of non-currency of the date of this report, the views and contents may not reflect the research analysts' current thinking. This document has been produced independently of the Issuer. While all reasonable care has been taken to ensure that the facts stated herein are accurate and that the ratings, forecasts, estimates, opinions and views contained herein are fair and reasonable, neither the research analysts, the Issuer, nor any of its directors, officers or employees, shall be in any way responsible for the contents hereof, and no reliance should be placed on the accuracy, fairness or completeness of the information contained in this document. No person accepts any liability whatsoever for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection therewith.

Analysts' Compensation: The equity research analysts responsible for the preparation of this report receive compensation based upon various factors, including the quality and accuracy of research, client feedback, competitive factors, and overall firm revenues, which include revenues from, among other business units, Investment Banking.

Investment Ratings

Fair Value Estimate

We estimate stock's fair value by computing a weighted average of projected prices derived from discounted cash flow and relative valuation methodologies. The choice of relative valuation methodology (ies) usually depends on the firm's peculiar business model and what in the opinion of our analyst is considered as a key driver of the stock's value from a firm specific as well as an industry perspective. However, we attach the most weight to discounted cash flow valuation methodology.

Target Price Estimate

While we believe that the fair value is underpinned by the future benefits stream and growth outlooks, which are primary drivers of value, the market might not align to the fair value estimate within the estimated investment horizon. Thus, we do not derive our target price from the fair value but from a trading perspective using the year projected earnings or book value and the respective target multiples. Notwithstanding, we are of the opinion that the variance between the two should not be too significant.

Ratings Specification

BUY: Target Price of the stock is above the current market price by at least 10 percent

HOLD: Target Price of the stock ranges between -10 percent and 10 percent from the current market price.

SELL: Target Price of the stock is more than **10 percent** below the current market price.



November 05, 2020

Definitions

Price Targets: Price targets reflect in part the analyst's estimates for the company's earnings. The achievement of any price target may be impeded by general market and macroeconomic trends, and by other risks related to the company or market, and may not occur if the company's earnings fall short of estimates.

Asset allocation: The recommended weighting for equities, cash and fixed income instrument is based on a number of metrics and does not relate to a particular size change in one variable.

Movements in Price Target

Company Name: Lafarge Africa Plc.

Date	Price (N)	Previous Target Price(N)	New Target Price (N)	Previous Recommendation	New Recommendation
05-Nov-2020	18.50	17.53	19.88	BUY	HOLD
27-May-2020	11.60	14.87	17.52	BUY	BUY

Company disclosures

Meristem or the analyst(s) responsible for the coverage may have financial or beneficial interest in securities or related investments discussed in this report, which could, unintentionally, affect the objectivity of this report. Material interests, which Meristem or the analyst(s) have with companies or in securities discussed in this report, are disclosed below:

Company	Disclosure
Lafarge Africa Plc	

- a. The analyst(s) hold(s) personal positions (directly or indirectly) in a class of the common equity securities of the company.
- b. The analyst responsible for this report, as indicated on the front page, is a board member, officer or director of the company
- c. Meristem beneficially owns 1% or more of the equity securities of the company
- d. Meristem has been the lead manager or co-lead manager of any publicly disclosed offer of securities of the company over the past 12 months.
- e. Meristem beneficially holds a major interest in the debt of the company
- f. Meristem has received compensation for investment banking activities from the company within the last 12 months
- g. Meristem intends to seek, or anticipates receipt of compensation for investment banking services from the company in the next 3 months
- h. The content of this research report has been communicated with the company, following which this research has been materially amended before its distribution
- i. The company is a client of the stock broking division of the Meristem group.
- j. The company is a client of the investment banking division of the Meristem group.
- Meristem is the registrar to the company.
- I. The company owns more than 5% of the issued share capital of Meristem
- m. Meristem has other financial or other material interest in the company.



November 05, 2020

Conflict of Interest

It is the policy of Meristem Securities Limited and its subsidiaries and affiliates (Individually and collectively referred to as "Meristem") that research analysts may not be involved in activities that suggest that they are representing the interests of Meristem in a way likely to appear to be inconsistent with providing independent investment research. In addition, research analysts' reporting lines are structured so as to avoid any conflict of interests.

For example, research analysts are not subject to the supervision or control of anyone in Meristem's Investment Banking or Sales and trading departments. However, such sales and trading departments may trade, as principal, on the basis of the research analysts' published research. Therefore, the proprietary interests of those Sales and Trading departments may conflict with your interests.

Important Disclosure

For U.S. persons only: This research report is a product of Meristem Securities, which is the employer of the research analysts who has prepared the research report. The research analysts preparing the research report are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analysts are not subject to supervision by a U.S. broker-dealer, and are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Mersitem Securities only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

Legal entity disclosures

Meristem Securities Limited is a member of The Nigerian Stock Exchange and is authorized and regulated by the Securities and Exchange Commission to conduct investment banking and financial advisory business in Nigeria. However, the company through its subsidiaries carries out stock broking, wealth management, trustees and registrars businesses which are regulated by the SEC and ICMR.

Copyright 2020 Meristem Securities Limited. All rights reserved. This report or any portion hereof may not be reprinted, sold or redistributed without the written consent of Meristem Securities Limited.